Premium
THE IMMUNOLOGIC DOUBLET OF LENALIDOMIDE PLUS OBINUTUZUMAB IS HIGHLY ACTIVE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA, RESULTS OF A PHASE I/II STUDY
Author(s) -
Fowler N.H.,
Samaniego F.,
Turturro F.,
Neelapu S.,
Forbes S.,
Westin J.,
Fayad L.,
Fanale M.,
Feng L.,
Arafat J.,
Neal E.,
Hagemeister F.,
Nastoupil L.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_140
Subject(s) - obinutuzumab , lenalidomide , medicine , rituximab , oncology , follicular lymphoma , phases of clinical research , neutropenia , gastroenterology , lymphoma , multiple myeloma , chemotherapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom